Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-29 03:52:38 Page View：47

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Ethical issues complicate the benefits of medical crowdfunding
Next article： Medical records are filled with copy

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Crinetics acromegaly drug succeeds in late

AresearcherworkinginthelabatCrineticsPharmaceuticalsinSanDiego.CourtesyCrineticsSANDIEGO—CrineticsPh

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

How to fix cancer clinical trials' diversity problem

Clockwisefromtopleft:STAT'sNicholasSt.Fleur(moderator);JudySewards,headofclinicaltrialexperienceatPf

Wikipedia

focus

explore

How to fix cancer clinical trials' diversity problem